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1. Introduction 
The healthy gastrointestinal tract is functionally maintained by an epithelial barrier, a 
monocellular layer that acts as a critical interface between the “outside” lumen and host 
tissues. This selectively permeable barrier controls the equilibrium between tolerance and 
immunity to microbes and non-self antigens. It is physically composed of epithelial cells 
linked through tight junctions, and it is reinforced by a mucus layer and the secretion of 
antimicrobial peptides such as defensins, cathelicidins and lysozymes. Intestinal epithelial 
cells are also responsible for the transport of water and nutrients while simultaneously 
preventing the uptake of noxious agents and luminal flora. Pathogens are selectively 
eradicated and should therefore be distinguished from the commensal flora to elicit a 
balanced inflammatory response. This capacity is tightly governed by pathogen recognition 
receptors, such as NOD proteins and the Toll-like receptors (TLRs). To avoid immunologic 
hyper-responsiveness against harmless intra-luminal food and bacterial antigens, the 
selective transport of small quantities of these antigens takes place by dendritic cells and M 
cells in Peyer's patches, leading to oral tolerance. 
Several defects related to intestinal barrier function have been found in patients with 
inflammatory bowel disease (IBD), but for many, it remains to be clarified whether these are 
primary defects or secondary bystander effects of the inflammatory state. Nevertheless, 
evidence suggests that a “leaky gut” is an early and possibly primary defect in IBD 
pathogenesis. It has been demonstrated that increased intestinal epithelial permeability in 
Crohn’s disease (CD) may indeed precede clinical relapse by as much as 1 year and that 
unaffected first-degree relatives of CD patients may also have barrier dysfunction. In 
addition, it is well known that mucosal barrier-breaking substances, such as non-steroidal 
anti-inflammatory drugs (NSAIDs), may cause flare-ups in IBD patients. Finally, transgenic 
animal models have clearly demonstrated that a unique defect in the intestinal epithelial 
barrier is a sufficient trigger of the development of chronic gut inflammation. The recent 
advances in genotyping technology have greatly improved the knowledge base regarding 
genetic susceptibility for IBD and have revealed several IBD-associated single nucleotide 
polymorphisms (SNPs) in genes involved in intestinal barrier function. 
In this chapter, we first describe the components of the normal intestinal barrier. Next, we 
focus on the different barrier anomalies found in IBD both at the genetic and molecular 
level. The current evidence for a role of these barrier disturbances in the inflammatory 
process is extensively discussed. As a final point, the different therapeutic strategies for 
protecting or restoring the barrier function of the gut during IBD are discussed. 
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2. Components of the normal intestinal barrier 
2.1 The physical barrier is composed of a tightly linked intestinal epithelial cell layer 
and a mucus shield 
The surface lining of the intestine is composed of a single cell layer of tightly linked 
columnar epithelial cells. Intestinal epithelial cells are polarised, possessing an apical 
surface facing the lumen and a basolateral surface that is in direct contact with the 
immune compartment of the underlying lamina propria. The cells are tightly sealed by 
intercellular protein complexes consisting of tight junctions, adherens junctions and 
desmosomes (see 2.1.2), thus creating two physical compartments that separate the 
outside lumen from the inner host immune system. As such, these epithelial cells serve as 
a physical line of defence against harmful components passing the lumen, including 
foreign antigens, bacteria and the toxins they produce. Simultaneously, this barrier acts as 
a selective filter that permits the passage of essential dietary nutrients, electrolytes and 
water across the epithelial layer.  
Selective transport through the intestinal epithelial membrane is accomplished in three 
ways: via the transcellular route, via the paracellular route and through microfold  
(M) cells (figure 1). The transcellular passage of amino acids, ions, sugars and short-chain 
fatty acids is performed by specific pumps and channels embedded in the cell membrane.  
This process is called transcytosis, and it involves the uptake of entities and their 
subsequent endosomal degradation. As such, the transport of intact proteins is limited, as 
they are degraded by the lysosomal system. The transcellular transport of bacteria and 
toxins is usually linked with mucosal inflammation. Paracellular transport refers to the 
passage of luminal materials through the space between the epithelial cells that  
is controlled by the intercellular junctional complexes. These complexes permit the 
diffusion of ions and solutes through the pores created by the protein structures and 
prevent the flux of larger entities such as microbes. Both the junctional pore size and the 
presence and activity of membrane pumps are highly regulated by such factors as 
cytokines and hormones, and these factors largely determine the passage and “leakiness” 
of the intestine. A final route of epithelial transport is mediated by M cells, which are 
typically located in overlying lymphoid aggregates called Peyer’s patches. Unlike other 
epithelial cells, M cells lack microvilli and a mucus coat and represent a “guarded 
gateway” for the entry of microbes that are quickly recognised by the underlying 
lymphoid tissue.  
2.1.1 Specialised epithelial cells  
The epithelial lining of the gastrointestinal tract is composed of self-renewing epithelial 
cells that are arranged as crypts and villus projections. Stem cells within the crypts  
give rise to different types of specialised epithelial cells that migrate to the tip of the 
villus, where they undergo programmed cell death. Paneth cells represent one exception 
because they remain in the crypts. In addition to its role in antigen trafficking, the 
intestinal epithelial lining represents an anatomic barrier (see 2.1.2). Moreover, epithelial 
cells play an active role in barrier protection; they produce mucus, regulate the 
composition of the mucus layer (see 2.1.3) and serve as antigen-presenting cells for the 
immune cells residing in the lamina propria (see 2.2). Several different types of specialised 
epithelial cells can be distinguished, each of which participates in specific barrier 
functions (Table 1). 
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Cell type Characteristics Role in barrier function 
 
Goblet cells 
 
Production and 
release of mucus and 
trefoil factors (see 
2.1.3) 
 
Formation of a semi-permeable mucus 
layer preventing direct contact and 
adhesion between microflora and 
epithelial cells. 
Increase in repair mechanisms and 
tight junctions by trefoil factors. 
 
Paneth cells 
 
Production and 
release of 
antimicrobial 
peptides 
Direct bactericidal or bacteriostatic 
effects elicited by defensins, lysosyme 
and phospholypase A2. Some 
enveloped viruses and fungi can be 
specifically lysed by these 
antimicrobial peptides. 
 
Enteroendocrine cells Production and 
release of serotonin 
Release of serotonin into the lamina 
propria activates nerve fibres resulting 
in the stimulation of mucin secretion 
from goblet cells and passive water 
efflux. 
 
M cells Selective uptake of 
bacteria and antigens 
from the lumen via 
endocytosis or 
phagocytosis 
 
Controlled stimulation of the gut-
associated immune system. 
Table 1. Main characteristics of the different epithelial cell types found in the gut and their 
role in intestinal barrier protection. 
2.1.2 Intercellular junction complexes 
Intestinal epithelial cells are sealed together by dynamic protein complexes composed of 
transmembrane proteins linked to the actin cytoskeleton through adaptor proteins. The 
intestinal epithelial cell lining in the gut is permanently self-renewing through the 
continuous migration of cells from the bottom of the crypt to the villus tip. To maintain the 
integrity of the epithelial barrier, intercellular complexes are rapidly assembled and 
disassembled without any dysfunction of the barrier function.  
At the ultrastructural level, contacts between cells can be classified as tight junctions, 
adherens junctions or desmosomes. On the apical side of the epithelial monolayer, cells are 
attached to each other by means of tight junctions. These can be easily identified by electron 
microscopy because they leave no free space between two cells, in contrast to other 
junctional complexes in which cells are separated by 15 to 20 nm. Tight junctions consist of 
three types of proteins: occludins, claudins and junctional adhesion molecules. These 
molecules are linked to the cytoskeleton by members of the zonula occludens (ZO) family. 
Below the tight junctions, cells are attached by adherens junctions composed of E-cadherin  
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Fig. 1. Components of the normal intestinal barrier. Polarized intestinal epithelial cells 
provide a physical barrier between the outer luminal surfaces (apical) from the inner host 
immune tissues (basolateral). Highly selective transport across this barrier is accomplished 
by transcellular and paracellular routes and through M cells. A thick glycoprotein layer 
prevents direct contact between luminal bacteria and the epithelial cells. Further overgrowth 
of bacteria is prevented by the secretion of Paneth cell-derived antimicrobial peptides such 
as defensins and secreted IgA molecules (sIgA) produced by plasma cells. Tolerance within 
the gut is mediated by the large number of tolerogenic dendritic cells that are able to sense 
the lumen for bacterial antigens, resulting in the development of regulatory T (Treg) cells. 
molecules that are connected via catenin proteins. Finally, desmosomes reside at the basal 
part of the epithelial cell and provide anchoring points for keratin filaments that are 
attached to intracellular desmoplakin, which connects the cytoskeleton to proteins 
belonging to the cadherin family. 
2.1.3 The extracellular mucus shield  
Throughout the gastrointestinal tract, intestinal epithelial cells are covered on the apical 
side with a viscous glycoprotein layer, although the sites of M cells are an exception. This 
layer acts as a lubricant for the propulsion of gut contents and prevents direct contact 
between bacteria and epithelial cells, thus preventing inappropriate immune reactions. 
The mucus layer is porous, permitting the diffusion of macromolecules required for 
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gastrointestinal absorption and digestion while impeding the invasion of bacterial-sized 
particles. 
Four major components can be found in the complex mixture of the mucus barrier: secreted 
mucins and trefoil peptides (produced by goblet cells), antimicrobial peptides (produced by 
Paneth cells) and immunoglobulin A (IgA) molecules (produced by B cells residing in the 
lamina propria).  
The mucus barrier consists of two layers: a thin, sterile inner layer and a bulkier outer mucus 
layer that contains bacteria. The outer mucus layer physically protects the underlying cells 
from luminal bacteria. However, another important function is that it represents a niche that 
houses the commensal bacteria colonising the gut, thereby maintaining a balanced microflora 
that facilitates digestion. This outer layer is a dynamic compartment that is continuously 
degraded by luminal flora and replaced by the underlying cells. The differentiation of goblet 
cells and the release of mucins and antimicrobial peptides are directly regulated by  
the microbial flora. In addition, pathogen recognition by innate mechanisms (see 2.2) leads to 
the production of cytokines, which consequently stimulate mucin release. High concentrations 
of antimicrobial peptides and secretory IgA, which exert immune pressure on luminal 
bacteria, are found in the inner layer of the mucus barrier. Bile salts, which are produced 
mainly in the small intestine, greatly contribute to the suppression of bacterial growth in the 
mucus coat. 
The mucus layer in the colon is thicker than that of the ileum. Furthermore, bile salt 
concentrations are much lower in the colon, whereas bacterial load and dwell time are 
higher. 
2.2 The innate defence system: Sensing microbe-associated molecular patterns 
When bacteria are able to break through the mucus barrier, either because of active 
pathogenic mechanisms or because the mucus layer is compromised, they reach the surface 
of epithelial cells. This triggers a rapid innate immune reaction mediated by TLRs and 
NOD-like receptors on the cell surface and inside epithelial cells, respectively. Rather than 
recognising specific antigens, these receptors discriminate self from non-self entities by 
recognising highly conserved molecular structures, the so-called microbe-associated 
molecular patterns. Examples include lipopolysaccharide (LPS), bacterial DNA, flagellin and 
peptidoglycan. Upon the binding of these ligands to their receptors, they recruit adaptor 
proteins, such as MyD88, inducing a signalling cascade that ends in the activation of nuclear 
factor kappa B (NFκB) and subsequent chemokine and pro-inflammatory cytokine 
expression, including tumour necrosis factor alpha (TNFα, see 4.1).   
At least 11 TLR homologues have been identified, each of which has the unique capacity to 
recognise a specific microbial pattern. The best-studied apical TLR is TLR4, which 
recognises LPS, a cell-wall constituent of Gram-negative bacteria. In contrast, TLR5 can bind 
bacterial flagella, and it is located on the basolateral side of epithelial cells, suggesting its 
involvement in the eradication of invading bacteria. 
The NOD-like receptors are expressed exclusively within the cell. NOD1 and NOD2 have 
been widely studied, and each binds to a specific moiety of peptidoglycan, the main 
constituent of the bacterial cell wall of both Gram-negative and Gram-positive bacteria. 
After ligand binding, these receptors recruit the Rip2 protein, which in turn also leads to the 
activation of NFκB. 
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The final outcome of innate signalling is the induction of pro-inflammatory cytokines and 
subsequent recruitment of phagocytes, which present bacterial antigens, leading to the 
activation of adaptive immune responses and clearance of the infection. Surprisingly, the 
deletion of TLR4 or MyD88 in mice leads to increased susceptibility to chemically induced 
colitis. Antibiotic therapy or germ-free cultivation of mice also results in a higher 
sensitivity to colitis. In addition, TLR4 signalling increases transepithelial resistance, 
indicating increased gut barrier function. It is clear that TLR and NOD signalling is 
important in maintaining a physiological state of immune activation to preserve intestinal 
homeostasis (see 2.3), and these signalling pathways are actively involved in repair 
mechanisms.  
2.3 The immunological barrier characterised by oral tolerance 
Once antigens invade the epithelial barrier, they are sensed by antigen-presenting cells 
(dendritic cells and resident macrophages), which prime naïve T cells in situ or after they 
migrate to the mesenteric lymph nodes. Activated T cells then differentiate into T helper 
type 1 (Th1), Th2, Th17 or regulatory T (Treg) cells and up-regulate specific gut-homing 
receptors (α4β7 integrin and CCR9) to exert their functions at the site of infection. Whereas 
invasive pathogens can actively intrude on gut epithelial cells or induce their own 
phagocytosis via M cells, non-invasive bacteria can enter dendritic cells because of their 
frequent sampling. In the gut, dendritic cells can access the lumen by opening the 
intercellular space through the expression of tight junction proteins without compromising 
epithelial barrier function.  
The balance between responsiveness towards foreign antigens and unresponsiveness 
towards self-antigens is critical because any breakdown of these mechanisms can lead to 
autoimmunity or an inability to respond to harmful infections. An intriguing question, 
therefore, is how the gut, which contains an enormous amount of food components and 
bacteria and houses an elaborate network of lymphoid tissue, is not in a state of massive 
inflammation as a result of the constant triggering of innate immune responses, both from 
epithelial cells and the underlying lymphoid cells. The control of such responses is called 
oral tolerance, and this control precisely defines a healthy mucosal barrier. Immune 
homeostasis in the gut utilises innate signalling triggered mainly by the commensal 
microflora and provides an environment rich in Treg cells, which produce anti-
inflammatory cytokines such as interleukin 10 (IL10).  
Oral tolerance is defined as the absence of a systemic immune response towards an antigen 
that has previously been encountered by the host. Thus, tolerance is an antigen-specific 
event. Together with anergy and apoptosis of antigen-specific T cells in the gut, the 
induction of antigen-specific Treg cells represents a method of actively inhibiting 
unnecessary inflammation. The key players in maintaining oral tolerance are the gut-
resident antigen-presenting cells, which produce regulatory and immunosuppressive 
cytokines and present antigens to naïve T cells. In particular, dendritic cells exert the 
greatest stimulatory effect on T cells, as they express high levels of MHC class II and co-
stimulatory molecules. Emerging evidence suggests that dendritic cells in the gut are 
conditioned to a tolerogenic state, mediated by transforming growth factor beta 1 (TGFβ), 
thymic stromal lymphopoietin (TSLP) and retinoic acid.  
An important role exists for TGFβ, a well-known immunosuppressive cytokine that is 
expressed abundantly in the gut. TGFβ inhibits the expression of the transcription factors T-
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bet and GATA-3, which are necessary for the differentiation of Th1 and Th2 cells, 
respectively. In addition, TGFβ stimulates cells to differentiate into Treg cells that express 
the transcription factor Foxp3, which in turn inhibits the expression of IL2 and results in 
reduced T cell proliferation. Finally, TGFβ induces Th17 cells that express the transcription 
factor RORγT and produce inflammatory cytokines IL17A, IL17F and IL22. Although these 
cells play an important role during infection, an excess of Th17 cells has been associated 
with tissue injury and chronic inflammation. The expansion of established Th17 cell 
populations is accomplished by IL23, a cytokine that alters intestinal homeostasis and that 
has been linked with susceptibility to IBD (see 3.2.5). 
2.4 Commensal bacteria 
Commensal bacteria are by definition non-pathogenic microbes (bacteria or yeast) that can 
colonise the intestinal environment and confer benefit to the host. Typically, these bacteria 
are known to play a role during food digestion. However, they also elicit considerable 
protective effects related to barrier function. A very important role of commensal bacteria 
relates to immunomodulation by promoting tolerogenic dendritic cell and Treg cell 
populations and inhibiting pro-inflammatory cytokine production as described above. For 
example, commensal bacteria can induce TSLP and TGFβ expression from epithelial cells. 
Some Lactobacillus species can increase mucus, IgA and defensin secretion, and several 
Bifidobacteria strains can directly inhibit adherence or invasion of specific pathogens into 
epithelial cells or inhibit their growth and destroy them. Finally, some commensals can 
strengthen epithelial junctional complexes by inducing the expression of host proteins in 
these complexes.  
3. Intestinal barrier dysfunction in IBD 
IBD is characterised by loss of controlled ion and water transport, which is a direct 
consequence of intestinal barrier dysfunction. Increased permeability in IBD is largely 
determined by tight junction deregulation and apoptosis of epithelial cells. Functionally, 
barrier loss is associated with uncontrolled immune responses because of increased bacterial 
translocation and high expression of inflammatory cytokines such as TNFα and IFNγ (in 
CD) and IL13 (in the case of ulcerative colitis (UC)). In addition, recent advances in 
metagenomic sequencing have greatly aided in the characterisation and understanding of 
the composition of microflora, which was found to be significantly altered in IBD (see 4.2.2).  
Although barrier dysfunction has indisputably been recognised as a component of IBD 
pathogenesis, the question whether these defects are a primary cause or a consequence of 
the chronic disease process remains unanswered. Over the last decade, evidence has 
mounted that intestinal barrier impairment may be the primary driver of IBD.  
3.1 Clinical data 
The first clue that an intestinal mucosal barrier defect could be an early pathogenic event in 
IBD came from studies of first-degree healthy relatives of patients with CD. It was found 
that these relatives exhibit increased intestinal permeability compared to that in unrelated 
control subjects despite the absence of inflammation.  
Complete mucosal healing appears to become the goal of future treatment for IBD. 
Preliminary data indicate that patients with complete mucosal healing have long-lasting and 
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deep remission. Interestingly, CD patients in remission with a persistent increase in 
intestinal permeability appear to have a greater risk of disease relapse. 
NSAID use, stress and smoking are known risk factors for IBD relapse. All of these factors 
are known to cause intestinal barrier dysfunction. NSAIDs inhibit the synthesis of mucosa-
protective prostaglandins, potentially leading to ulcerations and barrier breakdown. 
Prolonged psychological stress can induce ultrastructural epithelial abnormalities, increased 
bacterial translocation and low-grade inflammation. Finally, smoking is associated with an 
increase in apoptotic cell death of the intestinal epithelium, leading to conductive leaks in 
the gut barrier.  
3.2 Genetic and molecular evidence for intestinal barrier dysfunction in IBD 
Evidence suggests that increased gut permeability tends to be familial and is most likely 
genetically determined. Up to 40% of healthy first-degree relatives of patients with CD have 
been reported to exhibit increased intestinal permeability, compared to 5% in the control 
population. 
Epidemiological evidence clearly indicates that CD and UC are related polygenic diseases, 
and this has been supported by results from genetic association studies. In 2009, the 
International IBD Genetics Consortium (www.ibdgenetics.org), a network of researchers 
investigating the genetics of IBD, was established. At present, 20,000 CD and a similar 
number of UC cases have been collected, together with equivalent numbers of population-
based healthy controls, from several countries in Europe, North America and Australia. This 
collaboration has resulted in three large-scale genome-wide association studies for CD and 
UC in which multiple risk loci have been identified (Anderson et al., 2011; Barrett et al., 
2008; Imielinski et al., 2009). At the end of 2010, 99 replicated loci were found, and the genes 
within these loci have led to the discovery of new pathways involved in chronic gut 
inflammation. Many of these pathways involve intestinal barrier dysfunction, particular for 
UC (Barrett et al., 2009). Although the genome-wide scans have greatly improved our 
understanding of IBD pathogenesis, only an estimated 25% of the total genetic susceptibility 
can be explained by the currently identified disease-associated SNPs. In addition, due to 
linkage disequilibrium, the exact causative mutations remain to be identified. In the next 
section, the best-studied genetic associations involved in barrier function are discussed. 
3.2.1 Paneth cell dysfunction 
Paneth cells, which secrete antimicrobial factors, are found in the base of the crypts of the 
ileum. Many of the risk factors identified for IBD converge on Paneth cells and their 
function, including XBP1, NOD2, TCF4 and ATG16L1. The most intriguing finding of Paneth 
cell dysfunction was found in the intestinal epithelial-specific knockout of XBP1, a central 
regulator of endoplasmic reticulum (ER) stress. These mice spontaneously develop small 
bowel inflammation that markedly resembles some features observed in human IBD, such 
as crypt abscesses, leucocyte infiltration and ulcerations (Kaser et al., 2008). Among several 
identified abnormalities, including goblet cell depletion and accelerated cell renewal, Paneth 
cells were completely lost in these mice. These data demonstrate that XBP1 function, or ER 
stress in general, is critical for proper intestinal epithelial cell functioning. Obviously, cells 
with the highest protein synthesis burden (Paneth cells and goblet cells) suffer most from a 
deletion of ER stress mediators. In human IBD, increased ER stress can be detected in 
inflamed areas of the intestine (Bogaert et al., 2011). However, it remains to be investigated 
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whether this is a primary dysfunction or secondary to inflammation. One of the arguments 
that ER stress abnormalities are a primary event in IBD arises from genetic studies. Linkage 
of the region that is in close proximity to XBP1 has been established previously, and deep 
sequencing of this gene resulted in the identification of polymorphisms associated with both 
CD and UC. Rare XBP1 variants can be found to a much higher degree in IBD patients than 
in healthy controls. In particular, four non-synonymous mutations are present only in IBD 
patients. Interestingly, these mutations have been linked with hampered ER stress responses 
in vitro.  
Another well-characterised risk gene specifically for ileal CD is the innate immune receptor 
NOD2 (see 3.2.4). The finding that NOD2 is highly expressed in Paneth cells is particularly 
of interest because these cells provide host defence against microbes in the ileum, whereas 
they are not present in the normal colon. Lysozyme is an enzyme that breaks down bacterial 
cell wall components into muramyl dipeptide (MDP, GlcNAc-MurNAc), which is 
recognised by NOD2. Ileal expression of defensins was diminished in active regions in 
patients with NOD2 mutations, although this was not observed in the diseased colon. NOD2 
acts as an inducer of defensins, an effect that is lost in patients carrying a homozygous 
mutation in NOD2. Rather, these patients exhibit defective epithelial defence, proliferation 
of bacteria and the potential loss of epithelial barrier function. Similarly, variants in TCF4 
have been associated with ileal CD. TCF4 is a Wnt signalling transcription factor that plays a 
crucial role in Paneth cell development and directly activates defensin expression. 
Finally, a coding variant in ATG16L1, a gene involved in autophagy, was identified in CD. 
Mice with only a partial loss of this gene and CD patients carrying the causal ATG16L1 
variant exhibit structural defects in Paneth cell granules, the “protein storage” compartment 
of the cell (Cadwell et al., 2008). Proteins that are normally found within granules were 
visible in the cytoplasm. In addition, an altered transcriptional profile was found specifically 
in Paneth cells, consistent with a pro-inflammatory state. However, Atg16l1-deficient mice 
do not develop spontaneous intestinal inflammation. Unexpectedly, NOD2 with MDP 
activation has recently been reported to induce autophagy via an ATG16L1-dependent 
pathway, and monocytes isolated from patients carrying a CD-associated NOD2 variant fail 
to induce autophagy in response to MDP and bacterial infection.  
Taken together, the apparently divergent genetic findings point to a central impairment in 
Paneth cell function that is associated with IBD. Although the risk genes act at different 
levels, this can be explained by the fact that innate sensing, ER stress and autophagy are 
interconnected. 
3.2.2 Junctional complex genes  
A locus containing CDH1, which encodes E-cadherin, a component of adherens junctions, 
was found to be associated with UC and possibly with CD. With this finding, the first 
genetic link between colorectal carcinoma and chronic colonic inflammation was 
established, with routine colonoscopic surveillance recommended for those at greatest risk. 
Some mutations have been associated with reduced levels of E-cadherin at the plasma 
membrane and an accumulation of cytoplasmic cadherin. Another interesting genetic 
candidate gene for UC is hepatocyte nuclear factor 4 alpha (HNF4A), a transcription factor 
involved in the regulation of genes that comprise cell-cell contacts that is aberrantly 
expressed in human IBD. The full knockout of this gene is lethal, with embryological 
anomalies in the intestine including reduced epithelial cell proliferation, loss of crypt 
formation and defective goblet cell maturation. The conditional knockout of HNF4A in the 
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intestinal epithelium results in mice that develop increased epithelial permeability and 
alterations in mucin-associated genes. A strong association was found, specifically for UC, 
in a region containing laminin beta 1 (LAMB1), which encodes a subunit of the laminin family 
of proteins. Laminins are extracellular matrix glycoproteins that serve as major constituents 
of the basement membranes and play a key role in anchoring epithelial cells. Again, strongly 
reduced expression of laminins has been demonstrated in UC.  
The inflammatory cytokines TNFα and interferon gamma (IFNγ), both of which are highly 
expressed during active CD, significantly influence tight junction reorganisation, but the 
exact mode of action is incompletely understood. The pore-forming claudins (claudin 1, 3, 4, 
5 and 8), which can form size- and charge-specific paracellular pores, are up-regulated in 
CD, whereas occludin expression is reduced. Most likely, these changes occur as a 
consequence of inflammation, as they are not apparent during inactive disease. 
Nevertheless, determining how cytokines can modulate tight junction organisation is of 
great importance, as drugs targeting these cytokines have proven clinical efficacy in IBD. 
3.2.3 Genes involved in the constitution of the mucus shield 
A decrease of the number of goblet cells in IBD is associated with the reduced expression of 
mucins and a thinning of the mucus layer. Clinically, mucus diarrhoea is observed in UC, 
most likely because of the poor quality of the secreted mucus. Conversely, goblet cell 
dystrophy has been observed in CD with an increase in mucus production and decreases in 
antimicrobial peptides and tissue-regenerating trefoil factors. Moreover, colonic 
glycoprotein composition appears to be genetically determined, as it is more similar 
between monozygotic twins than between unrelated individuals. 
In human intestinal tissue isolated from patients with IBD, disturbed expression of several 
mucin genes has been reported, and allelic variants in MUC2, MUC3A, MUC4 and MUC13 
have been associated with IBD. 
Striking evidence for a role of mucus secretion in the development of colitis arise from mice 
that carry mutations in muc2. Aberrant mucus biosynthesis in these mice results in the 
spontaneous development of colitis with striking resemblance to some aspects of human 
UC. Targeted mutations in muc2 lead to misfolding of the mucin 2 protein in goblet cells 
followed by massive ER stress induction accompanied by increased intestinal permeability 
and enhanced production of pro-inflammatory cytokines in the distal colon.  
3.2.4 Genes involved in innate immunity 
The IBD1 locus, originally mapped in 1996, represents the best-replicated region exhibiting 
linkage specifically to CD and not to UC. In 2001, two groups simultaneously identified 
NOD2 as the first susceptibility gene for CD (Hugot et al., 2001; Ogura et al., 2001). Hugot 
and colleagues employed the positional cloning strategy, whereas Ogura and co-workers 
identified NOD2 by the positional candidate gene approach.  
The NOD2 protein belongs to the NOD1/Apaf-1 family, which comprises cytosolic proteins 
composed of an N-terminal caspase recruitment domain, a centrally located nucleotide-
binding domain, and a C-terminal leucine-rich regulatory (LRR) domain. Three common 
SNPs in NOD2 were independently associated with CD: two missense mutations [R702W 
(c.2104C>T, SNP8) and G908R (c.2722G>C), SNP12], and one frameshift mutation [1007fs 
(c.3020insC, SNP13)] that truncates the protein by 30 amino acids. All three variants alter the 
C-terminal domain of the protein, and they are located within or close to the LRR domain, 
which is involved in ligand recognition. The heterozygous carrier frequency of these 
www.intechopen.com
 
Intestinal Barrier Dysfunction: The Primary Driver of IBD? 
 
33 
variants in CD ranges from 30 to 50%, compared to frequencies of 3–15% for homozygous or 
compound heterozygote. By comparison, 8–15% of healthy controls are heterozygous, and 
0–1% of individuals carry a homozygous variant. The relative risk of developing CD if one 
of these variants is carried increases by a factor of 1.5 to 3 for heterozygous carriers, but the 
risk increases by a factor of 20 to 40 in homozygous or compound heterozygous individuals. 
Although this relative risk appears high, it must be stated that the absolute risk for 
developing CD is no more than 1 in 25 for homozygous carriers. This reduced penetrance 
can undoubtedly be explained by the requisite of environmental risk factors and/or 
additional genetic determinants. Clinically, 40% of healthy relatives of IBD patients who 
carry one of these SNPs have increased intestinal permeability. 
The Nod1/Apaf-1 family of proteins displays striking similarity to a class of disease 
resistance (R) proteins found in plants. Following specific recognition of pathogen products, 
these R proteins mediate a defence response associated with metabolic alterations and 
localised cell death at the site of pathogen invasion. The LRR domains of R proteins are 
highly diverse and appear to be involved in the recognition of a wide array of pathogen 
components. Similar to the R proteins, NOD2 appears to play an important role in innate 
and acquired immunity as a sensor of bacterial components. Specifically, NOD2 participates 
in the signalling events triggered by host recognition of specific bacterial motifs and 
subsequently activates NFκB, the key mediator in the production of pro-inflammatory 
mediators. Naturally occurring peptidoglycan fragments were identified as the microbial 
motifs sensed by NOD2, specifically MDP, which is found in Gram-negative and Gram-
positive bacterial peptidoglycans. 
The expression of NOD2 was first thought to be restricted to myeloid lineage cells, primarily 
monocytes. Moreover, its expression is enhanced by pro-inflammatory cytokines and 
bacterial components via NFκB, a mechanism that may contribute to the amplification of the 
innate immune response. Consistent with this observation, elevated NOD2 expression has 
been detected in inflamed areas of colonic tissue of CD patients. 
Although the function of NOD2 in bacterial sensing is widely accepted, its physiological 
function is less well understood. Consequently, the implications of the CD-associated 
mutations in disease onset and progression remain unclear. Several hypotheses have been 
postulated that involve both loss-of-function and gain-of-function mutations in NOD2, 
although the gain-of-function hypotheses have received criticism. The gain-of-function 
hypotheses evolved from NOD2 knockout and transgenic mice, but they are not consistent 
with the observations in humans. It is important to note that these hypotheses are not 
mutually exclusive and may be physiologically relevant in combination. 
In vitro and ex vivo experiments have indicated that the three CD-associated polymorphisms 
actually decreased the activation of NFκB and pro-inflammatory cytokine production, 
which are inconsistent with the observation that NFκB is up-regulated in patients. However, 
this might reflect a lack of primary innate immune triggering in response to bacterial 
invasion. As the three CD-associated variants of NOD2 are located in or near the LRR, it was 
suggested that bacterial sensing is impaired, thereby explaining the susceptibility to disease. 
Consequently, the clearing of bacterial products is inefficient, which may lead to a 
secondary, compensatory activation of NFκB independent of NOD2. Notably, peripheral 
blood mononuclear cells from individuals homozygous for the major disease-associated 
SNP13 mutation did not respond to synthetic MDP. These cells also exhibit defective pro-
inflammatory cytokine release after stimulation with MDP. Mononuclear cells isolated from 
CD patients carrying NOD2 polymorphisms produced significantly less IL1β, IL6 and IL10 
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after stimulation with adherent-invasive E. coli LF82 in a gene-dose effect. This was the first 
study in which aberrations were found in heterozygous carriers of SNP8 and SNP12 NOD2 
mutations, which represent the largest group of patients.  
In human monocyte-derived dendritic cell cultures, NOD2 agonists synergistically induce 
IL12 production in combination with TLR3, TLR4 and TLR9 agonists to induce Th1-lineage 
immune responses. This synergistic effect was lost in patients carrying a mutant NOD2 
protein. The inflammatory phenotype of CD is difficult to reconcile with decreases in TNFα 
and IL12 levels. However, it was recently demonstrated that the synergistic induction of 
IL10 in response to MDP and TLR stimuli was lost in NOD2 mutant monocyte-derived 
dendritic cells. IL10 is crucially involved in the down-regulation of the inflammatory 
process. It was thus postulated that IL10-mediated immune suppression is impaired, and 
the counter-effect for pro-inflammatory cytokines is lost, thereby contributing to chronic 
inflammation in CD.  
Incubation of normal murine macrophages with MDP was demonstrated to suppress IL12 
secretion induced by stimulation with TLR2 ligands. This suppression did not occur in cells 
lacking NOD2 or in cells expressing a mutant form of NOD2 during transfection 
experiments. Once secreted, IL12 promotes IFNγ production and the growth and 
differentiation of Th1 cells. A major concern, however, is the reproducibility of these results. 
Furthermore, NOD2 and TLR2 stimulation of human mononuclear cells isolated from 
patients with the 1007fs mutation led to a loss of the synergistic induction of pro-
inflammatory cytokines, which is also inconsistent with a TLR2 inhibitory function of 
NOD2. 
LPS, a cell wall component of Gram-negative bacteria, is a major inducer of inflammation, 
and its signalling is mediated through the cell-surface receptor TLR4. During intestinal 
inflammation, TLR4 is up-regulated on epithelial cells, macrophages and dendritic cells, 
thus providing a first line of defence against enteric Gram-negative bacteria. An association 
between a polymorphism in the LRR region of TLR4 has been reported within a Dutch CD 
and UC cohort. Allele frequencies of 11% were found in CD patients, versus 5% in healthy 
controls. The association was replicated twice but could not be reproduced in three other 
studies. This mutation was previously linked to decreased bronchial responsiveness to LPS 
and impaired LPS signalling. However, no functional defect, e.g., cytokine release or LPS 
recognition, has been attributed to heterozygous carriers among CD patients. However, 
TLR4 is generally up-regulated on intestinal epithelial cells of patients with IBD, 
contributing to prolonged and increased responsiveness to normal luminal bacteria. 
3.2.5 Genes involved in oral tolerance 
IBDs are characterised by a loss of tolerance towards commensal bacterial flora. Animal 
models of enteritis, such as the IL10 knockout model, do not develop disease when they are 
housed in a germ-free environment. Likewise, diversion of the faecal stream in IBD patients 
can stop the disease until the faecal stream is restored.  
Anti-inflammatory cytokines, such as IL10, play a crucial role in maintaining tolerance. 
Deletion of the gene encoding IL10 or its receptor (IL10R) in mice results in spontaneous 
small intestinal inflammation. IL10R mutations have been found in CD. These mutations 
lead to inefficient immunosuppression via IL10.  
Treg cells are important for the maintenance of intestinal self-tolerance. Concentrations of 
TSLP, a major inducer of Treg development, are reduced in patients with IBD. Although 
Treg numbers increase during active IBD, they are significantly lower when compared to 
www.intechopen.com
 
Intestinal Barrier Dysfunction: The Primary Driver of IBD? 
 
35 
non-IBD inflammatory conditions, such as diverticulitis. The addition of Treg cells in 
established colitis in mice results in complete remission of intestinal inflammation. 
The first large genome-scan for CD resulted in the identification of multiple genes involved 
in IL23/Th17 signalling (Barrett et al., 2008), with CD-associated SNPs in CCR6, STAT3, 
JAK2, IL23R and IL12B.  
3.3 Animal data 
Additional evidence that barrier dysfunction may be the primum movens in IBD can be 
derived from animal studies. One of the earliest histological signs of dextran sodium 
sulphate (DSS)-induced colitis, a commonly used mouse model of UC, is increased 
apoptosis in colonocytes. This finding occurs before any histological sign of inflammation, 
such as an influx of polymorphonuclear cells in the colonic mucosa. A similar finding has 
been observed in the SAMP1/Yit and IL10 gene-deficient mouse models of CD. These mice 
both exhibit a disturbance of the intestinal epithelial integrity prior to the onset of 
inflammation.  
Some genetically engineered mice with a primary defect in a component of the normal 
intestinal mucosal barrier (Muc2, Hnf4a gene-knockout mice) spontaneously develop chronic 
intestinal inflammation, suggesting that intestinal barrier disruption may be a primary and 
sufficient trigger of IBD. 
4. Strategies to defend or restore the gut barrier in IBD 
4.1 Currently used therapies 
Little is known about the barrier-protective actions of the currently used drugs in IBD 
treatment. 
Preparations of 5-aminosalicylic acid (5-ASA) are mainly used in the treatment of mild to 
moderate UC. The exact mechanism of action of 5-ASA is incompletely known. In the DSS-
induced colitis model, mesalazine both reduces colonic inflammation and permeability. It 
has been claimed that part of the mode of action of 5-ASA might rely on a reduction of  
IFNγ-induced epithelial barrier dysfunction during inflammation. 
Although sometimes used for maintenance of remission in patients with CD, methotrexate 
appears instead to promote barrier dysfunction by promoting the production of reactive 
oxygen species and by altering ZO-1. Hence, it can be speculated that the anti-inflammatory 
actions of methotrexate overrule its negative effects on intestinal barrier function in patients 
with CD. 
The introduction of anti-TNF agents was a breakthrough in the management of IBD.  
These biologics can rapidly induce remission and mucosal healing in both CD and  
UC patients. Anti-TNF agents share the ability to rapidly restore intestinal mucosal barrier 
function (within 2 weeks after a single infusion), which has been attributed to their  
strong anti-apoptotic effect on the gut epithelium rather than an effect on tight junction 
proteins. 
4.2 Experimental therapies 
Compounds with strong protective effects on the gut barrier often have spectacular efficacy 
in experimental gut inflammation, making them attractive candidates for the treatment of 
IBD. In this part, we give an overview of the most promising barrier-protecting molecules 
that might enter clinical practice in the future. 
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4.2.1 Prolyl hydroxylase-inhibiting compounds 
Active inflammation is associated with low levels of oxygen and nutrients. Severe intestinal 
mucosal hypoxia has been clearly demonstrated in both experimental colitis and human 
IBD. The intestinal epithelial cells lining the gut lumen are particularly prone to these 
decreased oxygen levels during inflammation because of their anatomic position, which is 
relatively far from the richly vascularised sub-epithelial mucosa (figure 2). Mucosal hypoxia 
will lead to epithelial inflammation and barrier dysfunction by stimulating the release of 
pro-inflammatory cytokines. Animals exposed to full-body hypoxia display increased 
colonic permeability and an increase in myeloperoxidase levels, which is a marker for 
neutrophil accumulation. 
The inhibition of cellular PHDs during hypoxia is an endogeneous adaptive system of the 
enterocytes aimed at protecting against hypoxia-induced cell death. As a result of PHD 
inactivation, both hypoxia-inducible factor 1 (HIF-1) and NFκB are activated. HIF-1 is a 
transcription factor of many genes involved in angiogenesis, metabolism and barrier 
preservation. Mice with a conditional knockout of HIF-1 in the intestinal epithelium are 
more susceptible to chemically induced colitis. NFκB is considered a pro-inflammatory 
transcription factor. However, it has recently been recognised that NFκB also has strong 
anti-apoptotic effects on the gut epithelium. Mice lacking NEMO, an important and essential 
positive regulator of NFκB, exhibit severe spontaneous colitis. 
PHD-inhibiting compounds have a very strong protective action in murine models of colitis 
and in a murine model of Crohn's ileitis. A strong inhibitory effect on intestinal epithelial 
apoptosis appears to be an important mode of action. Future studies must address the 
feasibility and safety of these molecules for human use (Hindryckx et al., 2011a) 
4.2.2 Probiotics 
The normal intestinal microflora plays an important role in maintaining intestinal health. 
These microflora protect against pathogens and maintain epithelial barrier integrity.  
A microbial imbalance in the gut (termed "dysbiosis"), with a relatively low proportion  
of beneficial flora and a relatively high proportion of potentially harmful flora, has been 
associated with IBD. For example, some patients with CD have remarkably reduced levels  
of Faecalibacterium prausnitzii, a butyrate-producing commensal bacterium of the gut. Low 
ileal levels of this bacterial species are associated with a higher risk of postoperative 
recurrence of ileal CD. In addition, oral administration of Faecalibacterium prausnitzii or its 
supernatant appears to correct the dysbiosis in experimental colitis and strongly reduces the 
severity of inflammation. Butyrate functions as a potent anti-inflammatory factor through 
the inhibition of NFκB activation and the increased production of mucins, antimicrobial 
peptides and tight junction proteins. Therefore, the selection of probiotic strains from the 
Clostridium IV cluster of bacteria that can locally produce butyrate is under investigation 
(Van Immerseel et al., 2010) 
Preliminary data on the use of probiotics in IBD patients to induce and maintain remission 
are promising, although the results appear to depend on the exact type of probiotic 
employed. For example, the addition of Saccharomyces boulardii to baseline therapy in 
patients with CD in remission may reduce the intestinal permeability and reduce the risk of 
relapse, although this was not observed for Lactobacillus casei GG. 
Several probiotics have been successfully tested in the preclinical IBD setting, but they 
remain to be examined in human disease. For example, Lactobacillus plantarum has been 
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demonstrated to ameliorate colonic epithelial barrier dysfunction and prevent colitis in IL10 
knockout mice. 
A careful selection of probiotic agents, combined with more convincing efficacy in large 
clinical trials, will determine whether some probiotics can be used to treat IBD in clinical 
practice. 
4.2.3 Flavonoids 
Flavonoids, a class of plant secondary metabolites, have long been recognised to exhibit 
some anti-inflammatory properties that may have potential applicability in IBD. For 
example, the flavonoid quercetin ameliorates experimental colitis in rats. In vitro studies 
have demonstrated that quercetin improves the barrier function of the gut by changing the 
expression and distribution of several tight junction proteins.  
Curcumin, a flavonoid extract from the spice turmeric, has been demonstrated to protect the 
mucosal barrier during rat enteritis. In a double-blind, multicentre trial of UC patients, the 
combination of curcumin and 5-ASA was superior in the prevention of disease relapse to 5-
ASA alone.  
Although evidence for a beneficial role in human IBD is still scarce, the available data on 
flavonoids suggest that it could be an effective and safe supplement to conventional IBD 
treatments. 
4.2.4 Phosphatidylcholine 
Phosphatidylcholine is a major phospholipid component of cell membranes. Insufficient 
phosphatidylcholine in the colonic mucus may lead to impaired phospholipid barrier 
function in UC, resulting in exposure to colonic commensal bacteria and mucosal 
inflammation. Exogenously administered phosphatidylcholine has anti-inflammatory 
properties in murine models of colitis. 
Phase IIa/b clinical trials have demonstrated that delayed-release phosphatidylcholine can 
induce clinical improvement and even remission in UC patients.  
4.2.5 Oxygenated perfluorodecalin   
PFD is a member of the perfluorochemical (PFC) family of chemicals, which are high-
density inert liquids with a remarkable capacity to dissolve high amounts of oxygen. These 
molecules can be used as powerful oxygen carriers and releasers into ischemic tissues. 
Topical administration of oxygenated PFCs has already been successfully used to treat 
difficult-to-treat chronic wounds, such as burns and diabetic ulcers. Intrarectal 
administration of oxygenated PFD both prevents and cures experimental colitis (Hindryckx 
et al., 2011b). The mechanism of action largely relies on a protective effect on colonic 
epithelial barrier function during inflammation. Due to its high density, PFD covers the 
colonic mucosa with an impermeable film, thereby preventing the influx of luminal antigens 
through the damaged colonic mucosa. In addition, the oxygen released by oxygenated PFD 
prevents apoptosis and stimulates proliferation of the colonocytes during inflammatory 
hypoxia (figure 2). 
No study on the use of oxygenated PFCs in human IBD has been conducted thus far. 
However, intrarectal administration of oxygenated PFCs is a typical example of a barrier-
promoting treatment that could be a very attractive strategy to heal therapy-resistant distal 
IBD or pouchitis. 
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Fig. 2. Targeting inflammatory hypoxia in IBD to protect the gut barrier during 
inflammation. IBD is characterized by dysfunctional blood  increased oxygen consumption 
by the active inflammatory infiltratea disturbed barrier function of the gut. Severe mucosal 
hypoxia during active IBD may lead to IEC death and further disruption of the gut barrier. 
Moreover, both hypoxia and inflammation stimulate the release of TNF-α, which also has a 
pro-apoptotic action on the gut epithelium. Prolyl hydroxylase- (PHD-) inhibiting 
compounds  mimick hypoxia and stabilize hypoxia-inducible factor-1 (HIF-1), which is a 
major transcription factor for cell survival and barrier-protection. Intra-luminal 
administration of oxygenated perfluorodecalin (O2-PFD) directly delivers O2 to the intestinal 
epithelium and suppresses inflammatory cytokines such as TNF-α.  
Both PHD-inhibitors and O2-PFD have been succesfully used in animal models of IBD. 
4.2.6 Growth factors 
Several observations have suggested that therapeutic growth factor administration 
attenuates the mucosal barrier function defect in CD.  
Epidermal growth factor (EGF) plays a key role in the healing response of the gut. In a small 
but randomised placebo-controlled trial, EGF enemas were superior to placebo in inducing 
remission at week 2 in mesalazine-treated patients with distal UC. 
Keratinocyte growth factor administration improved mucosal healing in murine colitis models 
but failed in a placebo-controlled trial in patients with active UC. 
In addition to improving the microbicidal activity of phagocytic cells, granulocyte-macrophage 
colony-stimulating factor (GM-CSF) also stimulates the proliferation of colonic epithelial cells. 
In a multicentre, randomised, controlled clinical trial using patients with active CD, 
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sargramostim (a recombinant version of GM-CSF) was superior to placebo in terms of 
disease remission and quality of life improvement. 
Transforming growth factors (TGFα, TGFβ) play an important role in mucosal defence and 
repair. Both TGF subtypes have been demonstrated to be crucially protective  
in murine colitis. Preliminary maintenance studies with a polymeric diet rich in  
TGFβ have been performed in both paediatric and adult CD patients with satisfactory 
results. 
Although the supplementation of some growth factors appears promising for treating IBD, 
concern exists regarding potential carcinogenic action, which should be addressed.  
4.2.7 Stem cells 
Stem cells (SCs) have pluripotent potential and can differentiate into every type of cell, 
including intestinal epithelial cells. This unique capacity may allow SCs to restore the 
intestinal epithelium as well as the immune balance in IBD. Currently, both haematopoietic 
SC transplantation and mesenchymal SC transplantation in IBD patients are under 
evaluation in phase III clinical trials. 
5. Conclusions 
IBDs are chronic, relapsing inflammatory conditions of the digestive tract, with an 
incompletely known multifactorial aetiology. Clinical, experimental and genetic data 
suggest that intestinal mucosal barrier dysfunction is a hallmark of IBD. The occurrence of 
increased permeability in healthy first-degree relatives of IBD patients and its predictive 
value of clinical relapse suggests that these events are of primary origin or are at least very 
early events in the pathogenesis of IBD. Therefore, restoration of the barrier integrity may be 
a highly effective treatment strategy to promote the recovery of the barrier function and 
help to alleviate inflammation.  
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